Shattuck Labs Reports Widened Q1 Net Loss of $14.77M Amid Rising R&D Costs
Summary
Shattuck Labs reported a widened net loss of $14.77 million, or $0.13 per share, for the first quarter of 2026, primarily driven by increased research and development expenses as the company advances its clinical and preclinical programs. The clinical-stage biotechnology firm recorded no revenue for the quarter. Despite the increased burn, the company reiterated its cash and equivalents position of $90.4 million is expected to fund operations into 2029, consistent with the outlook provided in its recent 10-K filing. This financial update highlights the expected cash consumption for a development-stage biotech. Traders will be watching for upcoming clinical catalysts, specifically the expected release of Phase 1 SL-325 data in Q2 2026 and the initiation of a Phase 2 SL-325 trial in Crohn's disease in Q3 2026.
At the time of this announcement, STTK was trading at $6.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.9M. The 52-week trading range was $0.71 to $8.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.